Light Horse’s CEO said the biotech’s initial focus will be on “high-value and historically challenging” oncology targets.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback